Biogen Inc. Common Stock
Market cap $31.9B
$219.29
BIIB
$219.29
+0.11% today
Buy with €1M virtual cash · No real money
Biogen Inc. Common Stock (BIIB) is a publicly traded company listed on the XNAS. As of September 17, 2026, Invest's signal rates BIIB a Buy, with the stock up 53% over the past year. You can practice trading BIIB risk-free with €1,000,000 in virtual cash.
Key stats
As of September 17, 2026
Market Cap
$31.9B
Volume
837K
52-wk High
$225.80
52-wk Low
$135.39
Day High
$219.41
Day Low
$215.33
P/E (TTM)
38.95
Revenue (TTM)
$10.0B
EPS (TTM)
$5.63
Performance
1M
+3.2%
6M
+20.3%
1Y
+52.6%
Invest signal · BIIB
BuyAlgorithmic signal from price trend, valuation, and fundamentals — educational only, not financial advice.
BIIB overview
AI overviewRevenue & EPS — last 8 quarters
QoQ rev +10.4%Revenue
$3BEPS (diluted)
$0.66 per shareLatest BIIB news
Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape
GlobeNewswire Inc. · 12h ago
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
GlobeNewswire Inc. · 2d ago
Hummingbird Bioscience Appoints Dr. James Garner as President
GlobeNewswire Inc. · 2d ago
Monoclonal Antibodies Market to Grow at 11.01% CAGR, Reaching USD 791.28 Billion by 2035 – SNS Insider
GlobeNewswire Inc. · Sep 9
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Zacks Investment Research · Sep 8
About Biogen Inc. Common Stock
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus.
Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Employees
7,500
30-Day Win Rate · BIIB
13 days
11 days
Last 24 sessions
How to practice trading BIIB
- 1
Use the BIIB buy panel above
Set a quantity and hit Buy at the real market price — right here, nothing to download.
- 2
Trade with €1,000,000 virtual cash
You get a million in virtual money instantly to invest, risk-free.
- 3
Create a free account to save it
Sign up in seconds to keep your portfolio and track its performance.
- 4
Track and compete
Watch your portfolio grow and climb the global leaderboard — or start a private league.
- 5
Prefer mobile? Get the iOS app
Invest is also free on the App Store, synced with your web account.
Top BIIB traders on Invest
Full leaderboardFrequently asked questions
Is BIIB a good stock to buy right now?
As of September 17, 2026, Invest's signal rates BIIB a Buy, based on its price trend, valuation, and fundamentals (P/E around 39.0), with the stock up 53% over the past year. This is an educational signal, not financial advice — the best way to test the thesis is to practice trading BIIB risk-free first.
What is Biogen Inc. Common Stock's (BIIB) market cap?
Biogen Inc. Common Stock has a market capitalization of approximately $31.9B, on trailing-twelve-month revenue of about $10.0B.
How has BIIB stock performed?
BIIB is up 53% over the past year and up 20% over six months. Its 52-week range runs roughly from $135.39 to $225.80. Past performance doesn't predict future results.
How can I practice trading BIIB for free?
On Invest you get €1,000,000 in virtual cash and can buy BIIB at real market prices right in your browser — no download and no real money at risk. Create a free account to save your portfolio and track its performance over time.
More stocks to practice
Designs the iPhone, Mac, and a huge services ecosystem.
Windows, Office, Azure cloud, and enterprise software.
The leading designer of AI and gaming GPUs.
E-commerce giant and the largest cloud provider (AWS).
Google Search, YouTube, Android, and cloud.
Facebook, Instagram, WhatsApp, and the metaverse.
Compare BIIB with peers